What are the specific diseases that Besudil/Yilaike mainly treats?

Belumosudil mesylate tablets (Belumosudil) is a kinase inhibitor mainly used to treat chronic graft-versus-host disease (GVHD). GVHD is a common post-transplant complication, especially after bone marrow transplantation (HSCT), in which the recipient's immune system attacks the donor tissue. Chronic GVHD is a serious and difficult-to-treat disease that usually affects multiple organs such as the skin, liver, and intestines, causing great pain to patients. Traditional treatment modalities often rely on glucocorticoids, but treatment options are very limited for those patients who are insensitive to or intolerant to hormonal therapy.

The primary therapeutic indication for besudil is chronic graft-versus-host disease. By inhibiting the activity of specific kinases, it slows or prevents the immune system's attack on recipient tissues, thereby alleviating the symptoms of the disease and delaying its progression. Besudil's unique mechanism of action makes it a new option for the treatment of chronic GVHD, especially when other treatments are ineffective, Besudil has demonstrated significant efficacy.

The indications for Besudil mainly includePatients with chronic GVHD aged 12 years and above, especially those who have an inadequate response to glucocorticoids or other systemic treatments. Its mechanism of action reduces the abnormal response of the immune system and controls the progression of GVHD by inhibiting the proliferation and activation of T cells. Therefore, Besudil has become an important treatment for this type of patients, helping them improve their quality of life and reduce their pain.

In addition toGVHD, the therapeutic potential of besudil is also being explored in other immune system-related diseases. As the clinical research and efficacy of besudil are better understood, it may be used to treat other related immune diseases in the future. Although the current main therapeutic area of u200bu200bbesudil is chronic GVHD, with the continued research on its drug mechanism and the accumulation of clinical data, it may play a role in the treatment of more immune system-related diseases in the future.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/rezurock